All In Biotech

NDA 021023 · Allergan

Restasis

Cyclosporine · Ophthalmic

Priority review

Last checked: Nov 20, 2026Latest source record: Oct 10, 2003 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Oct 10, 2003

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,166

250 Phase 3, 65 recruiting

FAERS reports

91,100

60,662 serious, 11,654 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 10, 2003 Original approval · Type 3 - New Dosage Form · priority review Review
1 products under this application
  • RESTASIS · CYCLOSPORINE 0.05% · EMULSION, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cyclosporine" as an intervention, any sponsor and status, largest first.

All 1,166 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective11,507
  • off label use9,378
  • eye irritation6,681
  • product use in unapproved indication3,873
  • eye pain3,413
  • nausea3,174
  • headache3,156
  • diarrhoea3,140
  • pyrexia3,112
  • fatigue3,078
  • vision blurred2,697
  • pain2,657

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004908
2005937
20061,072
20071,048
20081,793
20092,070
20102,639
20113,374
20122,715
20131,991
20142,616
20153,248
20164,300
20174,465
20184,346
20195,384
20205,813
20215,698
20227,320
20237,509
20248,330
20257,700
20265,818

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Restasis (Cyclosporine)

2024 spending

$1.29B

Beneficiaries

472,657

1,360,998 claims

Per beneficiary

$2,729

$10.20 per unit

View as table
YearSpending
2020$1,451,534,384
2021$1,628,418,856
2022$1,646,136,457
2023$1,501,664,198
2024$1,289,753,142

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,033 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.